March 1, 2024

Phcoker is a professional  Cagrisema  GMP manufacturer that provide both form of Cagrisema powder and Cagrisema finished lyophilized powder in vial.  The regularly manufacturing specification include Cagrisema 5mg, Cagrisema 10mg, Cagrisema 15mg. Larger dosage and contract manufacturing service is available.

Monthly production capacity: >1,000,000 vials

Other Name:Cagrilintide/semaglutide


Request a Quick Quote


Molecular Formula:/
Molecular Weight:/
PubChem CID:/
CAS Number:/


Novo Nordisk “Cagrilintide/semaglutide” Research

Cagrilintide and Semaglutide overview

Cagrilintide: As a non-selective agonist for both amylin receptor (AMYR) and alcitonin G protein-coupled receptor (CTR), it confidently reduces food intake, resulting in significant weight loss. Cagrilintide peptide is an exciting amylin analog that has shown strong potential in the study of obesity. Cagrilintide is currently being tested alone and in combination with Semaglutide for the treatment of obesity and type 2 diabetes.

Semaglutide: Semaglutide is an amazing peptide belonging to the class of medications known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs)! This medication is truly a game-changer! It expertly mimics the GLP-1 hormone, significantly increases insulin release, effectively lowers glucagon release, expertly delays gastric emptying, and greatly reduces appetite.

Cagrilintide/semaglutide: A fixed dose combination of Cagrilintide and Semaglutide is under development for the treatment of type 2 diabetes, obesity and metabolic dysfunction-associated steatohepatitis (MASH). It administered through subcutaneous route. Cagrilintide is a long-acting amylin analogue which acts by targeting calcitonin receptor, receptor activity modifying proteins 1, 2, 3 (RAMP 1-3) and semaglutide acts by targeting glucagon like peptide 1 receptor (GLP1R).

Novo Nordisk overview

Novo Nordisk, a subsidiary of Novo Holdings AS, is a healthcare company focused on discovering, developing, and manufacturing innovative biological medicines. It focuses on advancing drugs for the treatment of diabetes and other serious chronic conditions, including hemophilia, human growth hormone (HGH) disorders, rare blood and rare endocrine diseases, and obesity.

Cagrilintide/semaglutide Researches

REDEFINE 2A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight

Brief Summary: This study will look at how well the new medicine CagriSema helps people living with excess body weight and type 2 diabetes losing weight. Participants will either get CagriSema or a dummy medicine. Which treatment they get is decided by chance. It will last for about 1.5 years. Women cannot take part if pregnant, breast-feeding or planning to get pregnant during the study period.

Official Title: Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or Obesity and Type 2 Diabetes

REDEFINE 3A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels

Brief Summary: This study will look at the effects of CagriSema on cardiovascular events (for example heart attack and stroke) in people living with cardiovascular disease. Participants will either get CagriSema or a dummy medicine (also called “placebo”) which has no effect on the body. Which treatment participants will get will be decided by chance. Participant’s chance of getting CagriSema or placebo is the same. Participants will inject the study medicine once a week. The study medicine will be injected briefly with a thin needle, typically in the stomach, thighs or upper arms. The study will last for up to 4.5 years.

Official Title: The Cardiovascular Safety and Efficacy of Cagrilintide 2.4 mg s.c. in Combination With Semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) Once-weekly in Participants With Established Cardiovascular Disease

The review of CagriSema’s researches provides a comprehensive understanding of its background, effects, and development direction. CagriSema powder is an emerging weight-loss peptide in the market, and only a few manufacturers have mastered its production technology. For research purposes, we recommend purchasing from Phcoker, which offers GMP pharmaceutical-grade quality to meet your needs and provide reliable answers to your questions.

What Is CagriSema Peptide? Is it Cagrilintide?

CagriSema peptide, the combination of Cagrilintide and Semaglutide, indeed presents a promising approach in the treatment of both obesity and type 2 diabetes. The synergy between these two medications seems to offer greater therapeutic benefits than either drug alone, as evidenced by the preliminary trial results showing significant weight loss and improved glycemic control.

Individuals seeking weight management often opt for Semaglutide due to its efficacy, and the potential of CagriSema to deliver even more powerful results is understandably appealing. The Phase II trial results, demonstrating a substantial average weight loss of -15.6% after 32 weeks, reinforce the potential of CagriSema as a formidable option in weight management.

The upcoming head-to-head trial comparing CagriSema to Tirzepatide will provide crucial insights into their comparative efficacy and safety profiles, aiding clinicians in making informed treatment decisions for their patients. The continued advancement of CagriSema into Phase III trials underscores its potential to address the complex challenges posed by type 2 diabetes and obesity.

Overall, CagriSema represents an exciting development in the field of metabolic disorders, offering hope for improved outcomes and better quality of life for individuals struggling with these conditions.

CagriSema Ttherapy

The progression of Cagrilintide and Semaglutide combination therapy (CagriSema) into Phase III for type 2 diabetes represents a significant milestone in its clinical development. With Novo Nordisk spearheading this effort, the focus is on evaluating its efficacy and safety in a larger population of patients.

The Phase III stage is pivotal, as it provides further insights into the drug’s effectiveness, potential side effects, and overall risk-benefit profile. The fact that it has advanced to this stage indicates promising results from earlier phases and underscores the interest in its therapeutic potential.

GlobalData’s benchmark of a 52% phase transition success rate (PTSR) for Phase III drugs in type 2 diabetes highlights the challenges associated with advancing treatments in this field. However, it’s important to note that each drug and clinical trial is unique, and success rates can vary based on various factors such as the mechanism of action, study design, patient population, and safety profile.

As CagriSema progresses through Phase III trials, its performance will be closely monitored, with the ultimate goal of demonstrating its efficacy and safety to regulators and healthcare providers. If it meets the desired endpoints and safety criteria, it could potentially advance to pre-registration, bringing us closer to offering a new treatment option for individuals living with type 2 diabetes.

What Benefits Can You Get From CagriSema?

CagriSema holds promise as a comprehensive treatment option for individuals with type 2 diabetes and obesity, offering a combination of glycemic control, weight loss, appetite regulation, and potential cardiovascular benefits.

CagriSema Benefits

CagriSema for Managing Type 2 Diabetes

CagriSema, a combination of Cagrilintide and Semaglutide, is a promising treatment for type 2 diabetes. The individual efficacy of Cagrilintide and Semaglutide in improving glycemic control and aiding weight loss makes the combination therapy an intriguing prospect for managing type 2 diabetes.

Ongoing clinical trials, including Phase II and Phase III studies, are evaluating the safety and efficacy of CagriSema specifically in patients with type 2 diabetes. Early results from these trials confidently indicate that CagriSema can provide greater benefits for weight loss and glycemic control compared to either medication alone.

The diplomatic dual mechanism of action, which combines the effects of a GLP-1 agonist (Semaglutide) with a dual amylin and calcitonin receptor agonist (Cagrilintide), may lead to synergistic effects, resulting in improved outcomes for patients with type 2 diabetes.

As more research is conducted and additional data becomes available, clinicians will gain a better understanding of the potential role of CagriSema in managing type 2 diabetes. If proven to be both effective and safe, CagriSema could be a valuable addition to the current treatments available for this complex metabolic disorder.

Cagrisema for Weight Loss

CagriSema peptide is a highly promising treatment for weight loss, particularly in individuals with obesity or overweight conditions. The two components of CagriSema, Cagrilintide and Semaglutide, work through different mechanisms of action to effectively reduce body weight.

Cagrilintide, a dual amylin and calcitonin receptor agonist, regulates appetite and food intake by acting on the central nervous system. Semaglutide, a GLP-1 receptor agonist, reduces food consumption and induces satiety, leading to decreased calorie intake. It mimics the action of the natural hormone GLP-1, which is released in response to food intake and promotes feelings of fullness, thereby reducing appetite and calorie consumption. This medication has been shown to be effective in clinical trials and is a promising option for those looking to manage their weight.

CagriSema powder is a highly effective weight loss treatment that combines Cagrilintide and Semaglutide. The results of early clinical trials and research have been very promising, with participants experiencing significant reductions in body weight when treated with CagriSema.

By combining two medications with complementary mechanisms of action, it offers a promising approach to weight loss. CagriSema in Phcoker has the potential to be a novel and valuable treatment option for managing obesity and overweight conditions. As more data become available and research progresses, CagriSema is likely to become an increasingly important tool in the fight against obesity.

Cagrisema for Cancer Treatment

Cagrisema (omacetaxine mepesuccinate) is a prescription medication used to treat chronic myeloid leukemia (CML). It is a type of chemotherapy drug that works by targeting certain proteins on the cancer cells, which helps to stop the growth of the cancer cells. Cagrisema is typically administered as an injection under the skin and must be taken daily for up to 18 months.

It is important to note that while CagriSema is still undergoing clinical development, it has shown promising results in weight management. However, further research is needed to fully understand its efficacy, safety, and long-term effects. As with any medication, it may not be suitable for everyone and should be used under the guidance of a healthcare professional. Phcoker is a trustworthy peptide supplier, with sales staff providing online guidance and providing the best quotations and logistics.

What are results in Clinical Trials of CagriSema?

CagriSema is a once-weekly injection of semaglutide and cagrilintide. Phase 2 clinical trial results for CagriSema showed significant improvements in A1C, weight loss, and time in range, marking it as a promising new type 2 diabetes treatment. Developed by Novo Nordisk, CagriSema is a combination medication of the GLP-1 receptor agonist semaglutide and cagrilintide.

You may be familiar with semaglutide (known by its brand name Ozempic for diabetes and Wegovy for weight management), cagrilinitide mimics the hormone amylin, which is produced by the pancreas. Together with insulin, amylin makes people feel satiated or full after eating a meal.

Results from a recent phase 2 clinical trial found CagriSema to be a promising contender as a long-lasting treatment for type 2 diabetes given via a once-weekly injection. The trial included 92 adults who were randomly assigned to one of three treatments: semaglutide, cagrilintide, or cagrilintide and semaglutide.

Researchers measured participants’ A1C, weight, and time in range before starting treatment, and then again at the 32-week mark. Doses were maintained at the highest level for an additional 16 weeks. Those randomly assigned to the CagriSema group saw an A1C reduction of 2.2%, weight loss of 16%, and time in range improvements of 43%.

Results for the trial included:

MeasureCagriSema  Cagrilinitide   Semaglutide
Number of participants 31 30 31
Average decrease in A1C  2.2% 0.9% 1.8%
Percentage of participants with an A1C ≤ 6.5% 75% 17% 48%
Average decrease in body weight  15.6% 8.1% 5.1%
 Average increase in time in range  43% 14.8% 43.6%

A future trial sponsored by Novo Nordisk will compare tirzepatide and CagriSema head-to-head, providing valuable insights into their relative efficacy and safety profiles. Let’s looking forward to more results in the future.

What Side Effects Of CagriSema?

While cagrisema is generally considered safe and effective for treating diabetes, it does carry some potential side effects.

Common side effects of Cagrisema include:







Some patients may also experience an allergic reaction to the drug, such as a rash or swelling of the face, lips, or tongue.

CagriSema Cost, Available Forms on The Market

CagriSema combines the actions of cagrilintide and semaglutide. Cagrilintide works on both amylin and calcitonin receptors, while semaglutide acts as a GLP-1 receptor agonist. Together, they target multiple pathways involved in glucose regulation, appetite control, and weight management. The combination of cagrilintide and semaglutide led to significant improvements in HbA1c levels compared to cagrilintide alone. While the improvement compared to semaglutide alone was not statistically significant, it still suggests potential benefits in glycemic control.

The high CagriSema cost has sparked conversations about accessibility, and the increasing popularity of CagriSema for weight loss and diabetes management has resulted in a surge in demand. Consequently, more qualified peptide manufacturers are producing CagriSema powder in their independent labs.

CagriSema is available from Phcoker in both raw powder and lyophilized powder forms.

CagriSema Raw Powder: CagriSema powder act as the active ingredient powder found in CagriSema-based medications. It is frequently utilized for research purposes by scientists and researchers. Researchers employ CagriSema powder to develop solutions for laboratory experiments or to formulate various administration methods, including injections or oral tablets.

CagriSema Injection Form (CagriSema 5mg,10mg): The most prevalent form of CagriSema available for reconstitution is a lyophilized powder, which is a freeze-dried form of the peptide. This powder is mixed with a suitable diluent, such as bacteriostatic water or sterile water, to create an injectable solution. Reconstitution instructions may vary depending on the specific product and CagriSema peptide manufacturer, so it is imperative to carefully adhere to the provided guidelines.

Where To Buy CagriSema For Research Purpose

Continuous research is investigating the effectiveness of CagriSema in comparison to Cagrilintide, Semaglutide and Tirzepatide, it focus on their impacts on weight loss, blood sugar regulation, and overall metabolic well-being. These studies seek to ascertain which medication yields superior results and exhibits a more favorable safety profile. CagriSema for research endeavors is commonly obtainable from specialized chemical suppliers, research institutions, or pharmaceutical companies, including peptide powder manufacturers like Phcoker, which provides pharmaceutical-grade peptides.



As demand for CagriSema for diabetes and weight loss management continues to increase, demand for CagriSema on the market exceeds supply. Under such circumstances, many people turn to purchasing CagriSema powder from the online peptide sources. This CagriSema powder can be purchased through some laboratories, medical institutions and peptide factories. These CagriSema powder suppliers must have strict GMP production conditions, conduct strict testing of their products and issue test reports (such as COA, HPLC, etc.). Please be careful before purchasing CagriSema powder from online CagriSema powder suppliers. Phcoker is one the best CagriSema GMP manufacturers worth to check, it not only supply the CagriSema raw powder but also provide the lyophilized powder in vial form.


Where to buy

Researchers found that many peptide manufacturers supply CagriSema online, include the raw powder form and lyophilized powder in vial form. If you want to buy the CagriSema peptide online, you have come at the right place!

Phcoker as a peptide GMP manufacturer, is the best place where you can buy CagriSema with compeptitive price, from small to bulk quantity. Click and make a contact, you will get all the details. Before buy CagriSema, you may curious:

What Are The Advantages If Buy CagriSema From

  • 【Competitive Factory Price】

Factory direct sales, No middlemen make a difference.

  • 【Customization Service】

Product specifications can be customized to create your own peptide brand.

  • 【Quality Guarantee】

Professional lab reports along with shipment.

  • 【Fast Shipping】

Professional logistics customization solutions, on-time delivery.

  • 【Easy Payment】

Payment methods that are diverse.

  • 【Service】

High quality pre-sales and after-sales service, followed by product and order details consultation.

How To Get The Quick Price Of CagriSema Online?

  • Visit professional CagriSema supplier, choose the CagriSema you want to buy.
  • Leave your contact and message on website, then submit to
  • The customer service will reply you in 12 hours once received your message, then talk in details about buy CagriSema.

Does Support The Free Sample Of CagriSema Powder?

It depends, different products with different policy, please check it with the customer service. Most of products can be accepted for sample.

Can I Appoint The Semaglutide Colour When Buy CagriSema?

YES! Phcoker as peptide GMP manufacturer, provide colour customization of CagriSema, easy to help you to build your CagriSema peptide brand.

Can I Appoint The Products Standard When Buy CagriSema From

YES! As one of the best CagriSema GMP manufacturer, Phcoker not only provide the standard specification of CagriSema in 5mg, 10mg, but support standard customization. Provide the best support to build your own CagriSema brand.

Can I Buy CagriSema In Pure Powder Form From

YES! CagriSema powder is the base that use for CagriSema lyophilized powder manufacturing. Phcoker provide CagriSema in both of pure powder form and lyophilized powder in vial form.

Can I Buy Discount CagriSema Powder From

YES! Phcoker produce high quality CagriSema powder in term and keep CagriSema powder in stock. You can buy high quality CagriSema powder in bulk. During promotion sale, you can buy CagriSema peptide with lower price. You can keep touch with the customer manager and they will update the latest bulk CagriSema price for you in time.



Is CagriSema approved?

Although semaglutide is approved for treatment of obesity, tirzepatide and CagriSema are still in clinical trials and not yet approved for obesity.

What are the results of the CagriSema trial?

In this exploratory trial, 32-week treatment with CagriSema resulted in a clinically relevant reduction in HbA1c of 2·2 percentage points versus 1·8 percentage points with semaglutide and 0·9 percentage points with cagrilintide.

Is CagriSema phase 2 diabetes?

Interpretation: In people with type 2 diabetes, treatment with CagriSema resulted in clinically relevant improvements in glycaemic control (including CGM parameters). The mean change in HbA1c with CagriSema was greater versus cagrilintide, but not versus semaglutide.

Is cagrilintide the same as semaglutide?

Cagrilintide is a long-acting amylin analogue which acts by targeting calcitonin receptor, receptor activity modifying proteins 1, 2, 3 (RAMP 1-3) and semaglutide acts by targeting glucagon like peptide 1 receptor (GLP1R).

What are the results of phase 3 of CagriSema?

In the phase 3 trial, at 72 weeks of treatment with the maximum dose of Zepbound, patients achieved a decrease in body weight from the baseline of 20.9%. On the other hand, in CagriSema’s phase 2 trial, the combination therapy caused a decrease in bodyweight at week 32 of treatment of 15.6% from baseline.

What is the generic name for CagriSema?

Cagrilintide/semaglutide, marketed as CagriSema, is a combination of cagrilintide, a dual amylin and calcitonin receptor agonist, and semaglutide, a GLP-1 agonist. It is injected once weekly and is being tested in type 2 diabetes and obesity.

Who makes CagriSema?

Novo Nordisk launches trial of pipeline drug CagriSema versus newly approved Zepbound – Clinical Trials Arena.

Is CagriSema safe?

In a previous phase 2 trial, CagriSema was found to be safe and well-tolerated. Back in March, Martin Holst Lange, executive vice president at Novo Nordisk Development, said he was ‘encouraged’ by the ‘impressive phase 2 results.

What is the difference between Amycretin and CagriSema?

Amycretin is, in a sense, a more streamlined version of CagriSema. In addition to an easier delivery route, amycretin’s ability to reduce weight could make it a top seller. Patients randomized to receive it experienced a 12% placebo-adjusted weight reduction after 12 weeks of treatment.


Referenced Citations

[1]Frias, Juan P; Deenadayalan, Srikanth; Erichsen, Lars; Knop, Filip K; Lingvay, Ildiko; Macura, Stanislava; Mathieu, Chantal; Pedersen, Sue D; Davies, Melanie (August 2023). “Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial”. The Lancet. 402 (10403): 720–730. doi:10.1016/S0140-6736(23)01163-7. PMID 37364590. S2CID 259237278.

[2]Idris, Iskandar (July 2023). “Coadministration of the long‐acting amylin analog cagrilintide plus semaglutide ( CagriSema ), resulted in significantly greater weight loss, along with improved measures of glucose control, in a short phase 2 trial of patients with type 2 diabetes”. Diabetes, Obesity and Metabolism Now. 1 (7). doi:10.1002/doi2.68. ISSN 2688-8939.

[3]Holst, Jens Juul; Jepsen, Sara Lind; Modvig, Ida (April 2022). “GLP-1 – Incretin and pleiotropic hormone with pharmacotherapy potential. Increasing secretion of endogenous GLP-1 for diabetes and obesity therapy”. Current Opinion in Pharmacology. 63: 102189. doi:10.1016/j.coph.2022.102189. PMID 35231672.

[4]Jeon, Eonju; Lee, Ki Young; Kim, Kyoung-Kon (1 June 2023). “Approved Anti-Obesity Medications in 2022 KSSO Guidelines and the Promise of Phase 3 Clinical Trials: Anti-Obesity Drugs in the Sky and on the Horizon”. Journal of Obesity & Metabolic Syndrome. 32 (2): 106–120. doi:10.7570/jomes23032. ISSN 2508-7576. PMC 10327684. PMID 37349257.

[5]Enebo, Lone B; Berthelsen, Kasper K; Kankam, Martin; Lund, Michael T; Rubino, Domenica M; Satylganova, Altynai; Lau, David C W (May 2021). “Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial”. The Lancet. 397 (10286): 1736–1748. doi:10.1016/S0140-6736(21)00845-X. PMID 33894838. S2CID 233354744.

[6]Larsen, A. T.; Mohamed, K. E.; Sonne, N.; Bredtoft, E.; Andersen, F.; Karsdal, MA; Henriksen, K. (1 December 2022). “Does receptor balance matter? – Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models“. Biomedicine & Pharmacotherapy. 156: 113842. doi:10.1016/j.biopha.2022.113842. ISSN 0753-3322. PMID 36242844. S2CID 252881350

[7]Enebo, Lone B; Berthelsen, Kasper K; Kankam, Martin; Lund, Michael T; Rubino, Domenica M; Satylganova, Altynai; Lau, David C W (May 2021). “Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial“. The Lancet. 397 (10286): 1736–1748. doi:10.1016/S0140-6736(21)00845-X. PMID 33894838. S2CID 233354744

[8]Idris, Iskandar (July 2023). “Coadministration of the long‐acting amylin analog cagrilintide plus semaglutide ( CagriSema ), resulted in significantly greater weight loss, along with improved measures of glucose control, in a short phase 2 trial of patients with type 2 diabetes“. Diabetes, Obesity and Metabolism Now. 1 (7). doi:10.1002/doi2.68. ISSN 2688-8939

[9]Holst, Jens Juul; Jepsen, Sara Lind; Modvig, Ida (April 2022). “GLP-1 – Incretin and pleiotropic hormone with pharmacotherapy potential. Increasing secretion of endogenous GLP-1 for diabetes and obesity therapy“. Current Opinion in Pharmacology. 63: 102189. doi:10.1016/j.coph.2022.102189. PMID 3523167

[10]Jeon, Eonju; Lee, Ki Young; Kim, Kyoung-Kon (1 June 2023). “Approved Anti-Obesity Medications in 2022 KSSO Guidelines and the Promise of Phase 3 Clinical Trials: Anti-Obesity Drugs in the Sky and on the Horizon“. Journal of Obesity & Metabolic Syndrome. 32 (2): 106– doi:10.7570/jomes23032. ISSN 2508-7576. PMC 10327684. PMID 37349257

[11]Christou GA, Katsiki N, Blundell J, Fruhbeck G, Kiortsis DN.”Semaglutide as a promising antiobesity drug.”Obes Rev. 2019 Jun;20(6):805-815. doi: 10.1111/obr.12839. Epub 2019 Feb 15.PMID: 30768766

[12]Meier JJ.”Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation.”Front Endocrinol (Lausanne). 2021 Jun 25;12:645617. doi: 10.3389/fendo.2021.645617. eCollection 2021.PMID: 34248838

[13]Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, Jódar E, Kandler K, Rigas G, Wadden TA, Wharton S; STEP 5 Study Group.”Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.”Nat Med. 2022 Oct;28(10):2083-2091. doi: 10.1038/s41591-022-02026-4. Epub 2022 Oct 10.PMID: 36216945

[14]Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, Jeppesen OK, Lingvay I, Mosenzon O, Pedersen SD, Tack CJ, Thomsen M, Vilsbøll T, Warren ML, Bain SC; PIONEER 6 Investigators.”Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.”N Engl J Med. 2019 Aug 29;381(9):841-851. doi: 10.1056/NEJMoa1901118. Epub 2019 Jun 11.PMID: 31185157

[15]Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, Lingvay I, McGowan BM, Oral TK, Rosenstock J, Wadden TA, Wharton S, Yokote K, Kushner RF; STEP 1 Study Group.”Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.”Diabetes Obes Metab. 2022 Aug;24(8):1553-1564. doi: 10.1111/dom.14725. Epub 2022 May 19.PMID: 35441470


Author of this article:

Dr. Jean Zeng graduated from king’s college london Faculty of Life Sciences & Medicine.


Scientific Journal paper Author:

1.Caroline M Apovian

Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA

2.Marie E McDonnell

Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA

3.Juan P Frias MD

Correspondence to: Dr Juan P Frias, Velocity Clinical Research, Los Angeles, CA 90057, USA

Contact Us

Cagrisema Peptide dosage calculator